肾移植患者使用环孢素A与他克莫司治疗方案的成本效果分析  

Cost-Effectiveness Analysis of Cyclosporine A and Tacrolimus for Kidney Transplantations

作　　者：杨晨[1] 龚丽娴[1] 袁进[1] 吴新荣[1] 

机构地区：[1]广州军区广州总医院,广东广州510010

出　　处：《今日药学》2014年第6期429-430,434,共3页Pharmacy Today

基　　金：广东省医院药学研究基金(编号:2013A20)

摘　　要：目的对肾移植患者使用环孢素A胶囊（CsA）与他克莫司胶囊（FK506）进行药物经济学评价。方法 2012-01~12在本院行肾移植并在门诊接受治疗的60例患者,根据治疗方案,分为CsA组和FK506组,随访6个月,运用成本-效果分析法对2种药疗方案进行经济学评价。结果 CsA组与FK506组临床有效率分别为67.78%和84.45%（P〈0.05）,2组半年成本分别为21 699.12元和26636.82（P〈0.05）元,2组的成本-效果比分别为320.14和315.42。结论使用他克莫司胶囊用于肾移植患者的免疫抑制治疗具有更好的成本-效果比。Objective To evaluate the pharmacoeconomics of kidney transplantations with cyclosporine A and tacrolimus capsule. Methods From January to December 2012,60 outpatients were divided into CsA and FK506 group according to their treatment plan. All patients were followed up for 6 months. The cost-effectiveness analysis method was used to evaluate the pharmacoeconomics of the 2 treatment plan. Results Clinical effectiveness of CsA group and FK506 group were67. 78% and 84. 45%,respectively. The cost were 21 699. 12 yuan and 26 636. 82 yuan（ P 〈0. 05）. Cost-effective ratios were 320. 14 and 315. 42. Conclusion The tacrolimus capsules have better cost-effectiveness for kidney transplant patients.

关 键 词：环孢素A 他克莫司 肾移植 药物经济学 成本效果 

分 类 号：R699.2[医药卫生—泌尿科学]